Author

L. R. Forbes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1

Frequent Co-Authors

E. M. Mace· 2 shared I. K. Chinn· 2 shared J. S. Orange· 2 shared A. F. Carisey· 1 shared A. Freeman· 1 shared A. J. Faruqi· 1 shared A. Oler· 1 shared A. Vargas Hernandez· 1 shared

Activity by Year

2017-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. M. Mace

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic immunodeficiency and autoimmune disease reveal distinct roles of Hem1 in the WAVE2 and mTORC2 complexes

W. A. Comrie, M. C. Poli, S. A. Cook, M. Similuk, A. Oler, A. J. Faruqi, D. B. Kuhns, S. Yang, A. F. Carisey, B. Fournier, D. E. Anderson, S. Price, W. A. Chahla, A. Vargas-Hernandez, L. R. Forbes, , M. J. Lenardo

Hem1 loss-of-function mutations cause congenital immunodysregulation by disrupting WAVE2 and mTORC2 complexes, leading to immunodeficiency and immune hyperresponsiveness.

bioRxiv · Jul 4, 2019 · PreprintImmunology

Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations

A. Vargas Hernandez, E. M. Mace, O. Zimmerman, C. Zerbe, A. Freeman, S. Rosenzweig, J. W. Leiding, T. Torgerson, M. C. Altman, E. Schussler, C. Cunningham-Rundles, I. K. Chinn, I. C. Hanson, N. L. Rider, S. M. Holland, , L. R. Forbes

This study shows that ruxolitinib partially restores NK cell function in STAT1 GOF patients by reducing STAT1 phosphorylation and improving cytotoxic activity.

bioRxiv · Jun 28, 2017Immunology